Table 3.
Distribution of ABO and secretor status in studies with GII.4 genotype infections (symptomatic and asymptomatic). Only included are studies and/or genotypes with at least five representative samples.
| GII.4 Variant | Country | O | A | B | AB | Secretor | Non-Secretor | Type of Study | Reference |
|---|---|---|---|---|---|---|---|---|---|
| New Orleans 2009 | USA | N.A | N.A | N.A | N.A | + a | − | Active surveillance | [40] |
| Den Haag 2006b | USA | N.A | N.A | N.A | N.A | + | − | Active surveillance | [40] |
| Sydney 2012 | USA | N.A | N.A | N.A | N.A | + | − | Active surveillance | [40] |
| Den Haag 2006b | USA | + | + | + | + | 15/25 (60%) | 1/2 (50%) | Outbreaks | [51] |
| New Orleans 2009 | USA | + | + | + | + | 39/49 (80%) | 2/3 (66%) | Outbreaks | [51] |
| Sydney 2012 | USA | + | + | + | + | 5/9 (55%) | 0/2 (0%) | Outbreaks | [51] |
| New Orleans 2009 b | Ecuador | N.A | N.A | N.A | N.A | + | − | Birth cohort | [41] |
| Den Haag 2006b b | Ecuador | N.A | N.A | N.A | N.A | + | − | Birth cohort | [41] |
| Farmington Hills 2002 | USA | NA | NA | NA | NA | 16/23 (70%) | 1/17 (6%) | Challenge | [33] |
| Den Haag 2006b | China | N.A | N.A | N.A | N.A | 17/102 (17%) | 1/22 (5%) | Active surveillance | [44] |
| Hunter 2004 | Spain | N.A | N.A | N.A | N.A | 33/43 (77%) | 1/17 (6%) | Outbreak | [50] |
| N.A | Denmark | N.A | N.A | N.A | N.A | 29/52 (56%) | 0/9 (0%) | Outbreak | [30] |
| N.A | Sweden | N.A | N.A | N.A | N.A | 53/97 (55%) | 0/18 (0%) | Outbreaks | [49] |
| N.A | China | 7/50 (14%) | 25/52 (48%) | 9/28 (32%) | 3/5 (60%) | 41/115 (36%) | 0/15 (0%) | Outbreak | [42] |
| Den Haag 2006b c | China | 24/35 (69%) | 20/28 (71%) | 7/9 (78%) | 2/2 (100%) | 49/69 (71%) | 4/5 (80%) | Outbreak | [43] |
| Mixed d,e | Vietnam | N.A | N.A | N.A | N.A | 22/229 (10%) | 0/31 (0%) | Surveillance | [46] |
| Mixed | Burkina Faso | 1/71 (1%) | 0/34 (0%) | 7/55 (13%) | 1/4 (25%) | 9/164 (5%) | 1/44 (2%) | Passive surveillance | [47] |
| Mixed | Nicaragua | + | + | + | − f | + | − f | Passive surveillance | [53] |
| Unknown c | Israel | 16/30 (53%) | 17/34 (50%) | 7/16 (44%) | 6/11 (55%) | N.A | N.A | Outbreak | [54] |
| Unknown c | Israel | 36/66 (55%) | 28/77 (36%) | 21/45 (47%) | 7/25 (28%) | N.A | N.A | Outbreak | [54] |
a When real numbers are not publicly available; indicated by susceptible (+) resistant (−) reduced susceptibility (+/−); b The study also included Sydney (n = 4) and Osaka (n = 1) GII.4 variants; c Blood groups determined in both secretor and non-secretors; d Secretor and/or partial secretor included in secretor group; e Including Den Haag 2006b, New Orleans 2009 and Sydney 2012 variants; f Prevalence of AB and non-secretor is low in Nicaragua.